93 related articles for article (PubMed ID: 30256958)
1. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis.
Terashima T; Yamashita T; Sakai A; Ohta H; Hinoue Y; Toya D; Kawai H; Yonejima M; Urabe T; Noda Y; Mizukoshi E; Kaneko S
Jpn J Clin Oncol; 2018 Nov; 48(11):966-973. PubMed ID: 30256958
[TBL] [Abstract][Full Text] [Related]
2. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Ay S; Atcı MM; Arıkan R; Dülgar Ö; Özyükseler DT; Paksoy N; Doğan İ; Öztosun B; Taştekin D; Öven BB; Gümüş M
J Chemother; 2022 Nov; 34(7):465-471. PubMed ID: 35037592
[TBL] [Abstract][Full Text] [Related]
3. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2023 Jun; 58(6):575-585. PubMed ID: 37029223
[TBL] [Abstract][Full Text] [Related]
4. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Thalji SZ; Kamgar M; George B; Aldakkak M; Christians KK; Clarke CN; Erickson BA; Hall WA; Tolat PP; Smith ZL; Evans DB; Tsai S
Ann Surg Oncol; 2023 May; 30(5):3013-3021. PubMed ID: 36788189
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
Yoshida Y; Kobayashi S; Ueno M; Morizane C; Tsuji K; Maruki Y; Mori K; Watanabe K; Ohba A; Furuta M; Todaka A; Tsujimoto A; Ozaka M; Okano N; Yane K; Umemoto K; Kawamoto Y; Terashima T; Tsumura H; Doi K; Shioji K; Asagi A; Kojima Y; Suzuki E; Toshiyama R; Furukawa M; Naganuma A; Suzuki R; Miwa H; Ikeda M; Furuse J
Pancreatology; 2022 Dec; 22(8):1159-1166. PubMed ID: 36150984
[TBL] [Abstract][Full Text] [Related]
6. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
8. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
9. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T; Shirakawa T; Shimokawa M; Koga F; Kawaguchi Y; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Okabe Y; Makiyama A; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Mizuta T; Mitsugi K; Ureshino N
Int J Clin Oncol; 2021 May; 26(5):941-950. PubMed ID: 33483857
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
11. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan.
Furuse J; Osugi F; Machii K; Niibe K; Endo T
Int J Clin Oncol; 2024 Apr; 29(4):456-463. PubMed ID: 38353906
[TBL] [Abstract][Full Text] [Related]
12. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy.
van Eijck CWF; Sabroso-Lasa S; Strijk GJ; Mustafa DAM; Fellah A; Koerkamp BG; Malats N; van Eijck CHJ
Neoplasia; 2024 Mar; 49():100975. PubMed ID: 38335839
[TBL] [Abstract][Full Text] [Related]
13. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.
Yeh C; Bates SE
Semin Oncol; 2021 Feb; 48(1):34-46. PubMed ID: 33712267
[TBL] [Abstract][Full Text] [Related]
14. Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Merza N; Farooqui SK; Dar SH; Varughese T; Awan RU; Qureshi L; Ansari SA; Qureshi H; Mcilvaine J; Vohra I; Nawras Y; Kobeissy A; Hassan M
World J Oncol; 2023 Oct; 14(5):325-339. PubMed ID: 37869244
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
Kitamura H; Nakazawa J; Nagashima F; Andou M; Furuse J
Intern Med; 2023 Jun; 62(11):1573-1580. PubMed ID: 36223928
[TBL] [Abstract][Full Text] [Related]
17. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of first line FOLFIRINOX
Patel T; Miccio J; Cecchini M; Srikumar T; Stein S; Kortmanksy J; Johung K; Lacy J
J Gastrointest Oncol; 2021 Dec; 12(6):2547-2556. PubMed ID: 35070386
[TBL] [Abstract][Full Text] [Related]
19. [Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer].
Tsujie M; Fumita S; Ishikawa H; Kitani K; Satoi S; Fukuda S; Manabe H; Akashi Y; Wakasa T; Shiono H; Tamura T; Yukawa M; Inoue M
Gan To Kagaku Ryoho; 2019 Aug; 46(8):1259-1263. PubMed ID: 31501367
[TBL] [Abstract][Full Text] [Related]
20. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
